Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Deferred Revenue: 2013-2025

Historic Current Deferred Revenue for Ocular Therapeutix (OCUL) over the last 6 years, with Sep 2025 value amounting to $14.0 million.

  • Ocular Therapeutix's Current Deferred Revenue fell 1.34% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year decrease of 1.34%. This contributed to the annual value of $14.1 million for FY2024, which is 1.82% down from last year.
  • As of Q3 2025, Ocular Therapeutix's Current Deferred Revenue stood at $14.0 million, which was down 0.00% from $14.0 million recorded in Q2 2025.
  • Ocular Therapeutix's Current Deferred Revenue's 5-year high stood at $14.6 million during Q2 2023, with a 5-year trough of $13.0 million in Q4 2021.
  • Over the past 3 years, Ocular Therapeutix's median Current Deferred Revenue value was $14.2 million (recorded in 2024), while the average stood at $14.2 million.
  • Per our database at Business Quant, Ocular Therapeutix's Current Deferred Revenue rose by 7.41% in 2022 and then declined by 3.55% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Current Deferred Revenue (Quarterly) stood at $13.0 million in 2021, then grew by 7.41% to $14.0 million in 2022, then increased by 3.06% to $14.4 million in 2023, then declined by 1.82% to $14.1 million in 2024, then decreased by 1.34% to $14.0 million in 2025.
  • Its Current Deferred Revenue stands at $14.0 million for Q3 2025, versus $14.0 million for Q2 2025 and $14.1 million for Q1 2025.